In conclusion, methylation of 12 signature genes, including VEGFC, FBP1, NR3C1, NFE2L2, and DFNA5, may be associated with the prognosis of GC, and these genes-based risk models may be a useful tool in predicting prognostic outcomes for patients at earlier stages of disease. Here, NFE2L2 is linked to gastric cancer.